Mymetics Corp.
MYMXE
- -
USD
- -
- -
CIK
0001094814
ISIN
US62847M2070
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.48
5Y
- -
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Switzerland
- IPO Date
- Jan 1, 1997
- CIK
- 0001094814
- Website
- mymetics.com
- Similar Companies
- Business
- Mymetics Corporation (OTCQB: MYMX), a clinical-stage biotechnology company, develops virosome-based vaccines targeting mucosal immunity for infectious diseases including HIV, malaria, influenza, respiratory syncytial virus (RSV), and herpes simplex virus (HSV); its proprietary virosome platform utilizes lipid-based carriers with functional viral fusion proteins and rationally designed antigens to elicit broad systemic and mucosal immune responses, mimicking the safety of killed virus vaccines with the potency of live virus responses. The company offers virosome technology as an antigen delivery system applicable to enveloped viruses; key pipeline candidates encompass intra-nasal influenza vaccines, prophylactic HIV-1/AIDS vaccines, malaria transmission-blocking vaccines, RSV prophylactic vaccines partnered historically with Astellas Pharma and ClearPath, and HSV vaccines; it previously advanced preclinical COVID-19 vaccines in collaboration with Baylor College of Medicine. Founded in 1990 and headquartered in Epalinges, Switzerland, with research facilities in Leiden, the Netherlands, and U.S. registration in Washington, D.C., Mymetics operates primarily in Europe while targeting global markets for high-margin preventative vaccines against life-threatening pathogens; it maintains subsidiaries including Bestewil Holding BV and Mymetics BV for laboratory operations. In recent developments, Mymetics received a USD 8.67 million NIH grant in 2024, including USD 1.9 million for the first year, to advance its cold chain-independent, needle-free mucosal virosome HIV vaccine candidate toward clinical trials in partnership with Texas Biomedical Research Institute and the University of Louisiana at Lafayette; the company wound down operations of its Dutch subsidiaries Bestewil Holding BV and Mymetics BV in July 2023 amid liquidity challenges and terminated all but one employment agreement to implement cost reductions while pursuing strategic alternatives such as asset sales; as of March 2024, the Mymetics group reported being wound down, though its CEO continued HIV vaccine efforts under the NIH funding, and the entity remains listed on OTCQB with ongoing SEC reporting obligations through at least 2023.